Avinger (STU:VG20) Change In Receivables : €-0.03 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Avinger Change In Receivables?

Avinger's change in receivables for the quarter that ended in Jun. 2024 was €0.41 Mil. It means Avinger's Accounts Receivable declined by €0.41 Mil from Mar. 2024 to Jun. 2024 .

Avinger's change in receivables for the fiscal year that ended in Dec. 2023 was €0.07 Mil. It means Avinger's Accounts Receivable declined by €0.07 Mil from Dec. 2022 to Dec. 2023 .

Avinger's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.87 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Avinger's Days Sales Outstanding for the three months ended in Jun. 2024 was 46.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Avinger's liquidation value for the three months ended in Jun. 2024 was €1.88 Mil.

Avinger Change In Receivables Historical Data

The historical data trend for Avinger's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avinger Change In Receivables Chart

Avinger Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.22

0.08

0.25

0.07

Avinger Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Receivables	Get a 7-Day Free Trial															0.09	0.09	-0.19	-0.35	0.41

Avinger Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03 Mil.

Avinger (STU:VG20) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Avinger's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.865	/	1.716	*	91
=	46.00

2. In Ben Graham's calculation of liquidation value, Avinger's accounts receivable are only considered to be worth 75% of book value:

Avinger's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.181	-	8.865	+	0.75 * 0.865	+	0.5 * 3.827
=	1.88

Avinger Change In Receivables Related Terms

Thank you for viewing the detailed overview of Avinger's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Avinger Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avinger Inc (STU:VG20) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AVGR:USA

Address

400 Chesapeake Drive, Redwood City, CA, USA, 94063

Website

https://avinger.com

Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

Avinger Headlines

No Headlines